Krystal Biotech, Inc. (KRYS) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa.
Is Krystal Biotech, Inc. stock overvalued or undervalued in 2026?
Krystal Biotech, Inc. (KRYS) trades at 40.1× earnings (P/E). No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Krystal Biotech, Inc.
Market cap $9B · 52 weeks $198 – $378 (22 % below the high) · P/E 40.1× · 2027 est. P/E 33.4× · Dividend none · Next earnings February 16, 2027 · expected EPS $1.91 · Closing price, Nov 2 · accounts published Nov 2.
- Valuation: P/Sales 18.0× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 7 of 8 (on track).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.7 %, fails.
- Market cap / Cash 10.3×, fails.
- Annual cash burn $6.94, passes.
- Total Debt 0.0×, passes.
Against its peers (reference peers) — Krystal Biotech, Inc.: P/E 40.1×; EV/EBITDA 34.4×; ROIC 15.8 %; $8.8B. Protagonist Therapeutics, Inc. (P/E 135×; EV/EBITDA 100×; ROIC 6.7 %; $9.0B), Caris Life Sciences, Inc. (P/E 89.7×; EV/EBITDA 54.8×; ROIC 14.7 %; $9.1B), TG Therapeutics, Inc. (P/E 21.9×; EV/EBITDA 70.4×; ROIC 9.9 %; $9.2B).
Profitability
| Return on Equity | 17.02% |
| Return on Invested Capital | 15.75% |
| Return on Assets | 14.20% |
| Gross Margin | 67.87% |
| Operating Margin | 48.44% |
| Net Margin | 47.91% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 7.89 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 39.03 |
Price Performance
| 1 month | -8.19% |
| 3 months | -9.17% |
| Year-to-date | +20.02% |
| 1 year | +49.56% |
| 3 years | +142.24% |
| 5 years | +475.12% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of KRYS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks